Durata Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses. The Company enroll and dose patients in two global Phase III clinical trials with its product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections (abSSSI). Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing. In addition to abSSSI, the Company focuses on the development of dalbavancin for additional indications, including osteomyelitis, diabetic foot infection and pneumonia. As of December 31, 2011, Dalbavancin had already completed three Phase III clinical trials, in which more than 1,000 patients in total received dalbavancin.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:DRTX
- CUSIP: 26658A10
- Web: N/A
- 200 Day Moving Avg: $19.00
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -17.64
- P/E Growth: 0
Frequently Asked Questions for Durata Therapeutics (NASDAQ:DRTX)
What is Durata Therapeutics' stock symbol?
Durata Therapeutics trades on the NASDAQ under the ticker symbol "DRTX."
Who are some of Durata Therapeutics' key competitors?
Some companies that are related to Durata Therapeutics include Amgen (AMGN), Celgene (CELG), Gilead Sciences (GILD), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Grifols SA, Barcelona (GRFS), Incyte (INCY), Illumina (ILMN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Seattle Genetics (SGEN), Jazz Pharmaceuticals plc - (JAZZ), TESARO (TSRO), Alnylam Pharmaceuticals (ALNY), Exelixis (EXEL), BIO-TECHNE Corp (TECH) and Kite Pharma (KITE).
How do I buy Durata Therapeutics stock?
Shares of Durata Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Durata Therapeutics stock cost?
One share of Durata Therapeutics stock can currently be purchased for approximately $24.16.
Consensus Ratings for Durata Therapeutics (NASDAQ:DRTX) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Durata Therapeutics (NASDAQ:DRTX)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Durata Therapeutics (NASDAQ:DRTX)Earnings History by Quarter for Durata Therapeutics (NASDAQ:DRTX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Durata Therapeutics (NASDAQ:DRTX)
Current Year EPS Consensus Estimate: $-2.97 EPS
Next Year EPS Consensus Estimate: $-1.37 EPS
Dividend History for Durata Therapeutics (NASDAQ:DRTX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Durata Therapeutics (NASDAQ:DRTX)Insider Trades by Quarter for Durata Therapeutics (NASDAQ:DRTX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/12/2014||John Patrick Shannon Jr||Insider||Buy||3,000||$13.72||$41,160.00|| |
|6/12/2014||Paul R Edick||CEO||Buy||3,000||$15.23||$45,690.00|| |
|5/12/2014||Schutter Richard De||Director||Buy||15,000||$15.57||$233,550.00|| |
|3/21/2014||Aisling Capital Iii Lp||major shareholder||Sell||100,649||$15.74||$1,584,215.26|| |
|12/3/2013||Lisa Giles||Director||Buy||1,000||$10.95||$10,950.00|| |
|5/20/2013||Paul R Edick||CEO||Buy||3,000||$7.09||$21,270.00|| |
|8/14/2012||Paul R Edick||CEO||Buy||5,000||$8.65||$43,250.00|| |
Headline Trends for Durata Therapeutics (NASDAQ:DRTX)
Latest Headlines for Durata Therapeutics (NASDAQ:DRTX)
Durata Therapeutics (DRTX) Chart for Sunday, May, 28, 2017